Efficacy and safety of curcumin in patients with hand osteoarthritis: a pilot double-blinded randomised controlled trial.

2025-10-06
BMC complementary medicine and therapies 25(1)
- Panithan Tuntiyatorn
- Chawanin Lerspongpaibool
- Thepparat Kanchanathepsak
- Ittirat Watcharananan
- Tulyapruek Tawonsawatruk

PubMed: 41053771
DOI: 10.1186/s12906-025-05096-2

Study Design

Type: Randomized Controlled Trial (RCT)
Population: 27 patients over 50 years old diagnosed with hand osteoarthritis (13 in the curcumin group and 14 in the placebo group)
Methods: Pilot prospective double-blind, randomized controlled trial; three-month oral administration of either a turmeric capsule containing curcumin (170 mg/day) or a placebo
Blinding: Double-blind
Duration: three months
Funding: Unclear

Background

Curcumin, a substance in Turmeric spices, has been shown to exhibit anti-inflammatory and chondroprotective properties in several preclinical studies. However, there is limited research on the efficacy and side effects of oral curcumin in treating hand osteoarthritis. Thus, the primary aim of this pilot study was to assess the therapeutic effects and potential adverse effects of curcumin in patients with hand osteoarthritis, specifically in terms of pain reduction, improvement in functional outcomes, and relevant blood test parameters.

Method

This pilot prospective double-blind, randomized controlled trial included patients over 50 years old diagnosed with hand osteoarthritis. Participants received a three-month oral administration of either a turmeric capsule containing curcumin (170 mg/day) or a placebo. The outcomes measures included the Visual Analogue Scale (VAS) for pain, the Disabilities of Arm, Shoulder, and Hand (DASH) score, hand grip and pinch strength, as well as side effects and blood tests at one, two, three, and six months.

Results

Twenty-seven patients were enrolled in this study-13 in the curcumin group and 14 in the placebo group. Baseline characteristics were similar between both groups. Although patients in the curcumin group showed reductions in VAS pain scores and improvements in DASH scores after one month, the differences were not statistically significant. However, by the third month, patients in the curcumin group demonstrated significant reductions in VAS pain scores at rest and during activity compared to the baseline scores, with mean differences of 1.37 ± 0.64 (p-value = 0.032) and 1.74 ± 0.73 (p-value = 0.017), respectively. Additionally, their DASH scores improved significantly with a mean difference of 11.84 ± 5.88 (p = 0.044). One patient in the curcumin group experienced gastrointestinal (GI) side effects, leading to withdrawal from the study, but no other adverse effects were reported.

Conclusion

Based on the results of this pilot study, the authors conclude that a three-month regimen of low-dose oral curcumin may improve pain and functional scores in patients with hand osteoarthritis compared to placebo. However, GI discomfort remains a potential side effect to monitor. Overall, curcumin appears to be a safe and feasible alternative treatment option for hand osteoarthritis, and a larger, definitive randomised controlled trial is warranted.

Trial registration

The trial has been registered in the Thai Clinical Trials Registry(TCTR) database. The identification number is TCTR20210929003.

Research Insights

Turmeric→Improved DASH Score
Although patients in the curcumin group showed reductions in VAS pain scores and improvements in DASH scores after one month, the differences were not statistically significant.
Effect
Neutral
Effect size
Small
Dose
170 mg/day
Turmeric→Reduced Pain
Although patients in the curcumin group showed reductions in VAS pain scores ... after one month, the differences were not statistically significant.
Effect
Neutral
Effect size
Small
Dose
170 mg/day
Turmeric→Reduced Pain During Activity
and during activity ... 1.74 ± 0.73 (p-value = 0.017)
Effect
Beneficial
Effect size
Moderate
Dose
170 mg/day
Turmeric→Reduced Pain at Rest
by the third month, patients in the curcumin group demonstrated significant reductions in VAS pain scores at rest ... with mean differences of 1.37 ± 0.64 (p-value = 0.032)
Effect
Beneficial
Effect size
Moderate
Dose
170 mg/day

Adverse Events Reported

Turmeric→Overall tolerability
One patient in the curcumin group experienced gastrointestinal (GI) side effects, leading to withdrawal from the study, but no other adverse effects were reported.
Finding
Reported
Turmeric→gastrointestinal side effects
One patient in the curcumin group experienced gastrointestinal (GI) side effects, leading to withdrawal from the study, but no other adverse effects were reported.
Finding
Reported